Metronidazole Noridem

Metronidazole, the active ingredient in Metronidazole Noridem, is a nitroimidazole antibiotic presented as an intravenous solution for intravenous use. It treats anaerobic bacterial and protozoal infections in adult and pediatric patients as prescribed by a qualified health professional.

GNH USA supplies Metronidazole Noridem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Metronidazole is indicated for a range of anaerobic and protozoal infections. - Anaerobic bacterial infections: eradicates susceptible anaerobes causing intra‑abdominal and soft‑tissue infections. - Bacterial vaginosis: restores normal vaginal flora by eliminating Gardnerella and related organisms. - Trichomoniasis: eliminates Trichomonas vaginalis, relieving symptoms and preventing transmission. - Intra‑abdominal infections: provides systemic coverage for mixed aerobic‑anaerobic peritonitis and abscesses. - Pelvic inflammatory disease: treats polymicrobial PID where anaerobes are implicated.

Metronidazole may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Metallic taste: transient dysgeusia during infusion. - Headache: mild, often resolves without intervention. - Diarrhea: loose stools, usually self‑limited. - Skin rash: mild erythema or pruritus.

Serious or Rare Side Effects: - Seizures: rare neurotoxic events, especially with high plasma levels. - Peripheral neuropathy: tingling or numbness with prolonged therapy. - Severe allergic reaction: anaphylaxis or Stevens‑Johnson syndrome. - Hepatotoxicity: elevated liver enzymes or jaundice. - Hematologic abnormalities: neutropenia or thrombocytopenia.

Metronidazole requires careful use in specific clinical situations. - Pregnancy: Category B – generally considered safe, but use only if clearly needed. - Breastfeeding: Small amounts excreted in milk; weigh benefits against potential infant exposure. - Alcohol interaction: Avoid alcohol during and for 48 hours after therapy to prevent disulfiram‑like reaction. - Renal or hepatic impairment: Dose may need adjustment; monitor function. - Drug‑induced neuropathy: Limit duration when possible; monitor for sensory changes. - Store below 25°C: keep in original container, protect from light and moisture.

Metronidazole can affect or be affected by several concomitant medicines.

Major Interactions (Avoid): - Disulfiram: concurrent use can cause severe flushing, tachycardia, and hypotension. - Warfarin: increased anticoagulant effect may raise bleeding risk. - Lithium: may raise serum lithium levels, risking toxicity.

Moderate Interactions (Monitor Closely): - Cimetidine: may raise metronidazole plasma concentrations. - Phenobarbital or phenytoin: may reduce metronidazole efficacy by increasing metabolism. - Alcohol: can precipitate a disulfiram‑like reaction; advise abstinence.